U
US WorldMeds
Closely-held, Kentucky-based specialty pharmaceutical company. Our mission is to develop, license and commercialize
About US WorldMeds
US WorldMeds, LLC is a healthcare company focused on developing, licensing, and marketing meaningful and accessible healthcare products. The company operates in the pharmaceutical industry, primarily serving patients, healthcare providers, and communities affected by opioid overdoses. US WorldMeds' flagship product, ZIMHI, is a high-dose naloxone injection approved by the FDA for emergency treatment of opioid overdoses. The company generates revenue through the sale of its pharmaceutical products, leveraging partnerships and licensing agreements to expand its market reach. US WorldMeds aims to improve patient outcomes and foster a thriving community of patients, employees, and shareholders. The business model is centered around innovation, patient care, and community impact.
Source: Dealroom company dataAt a glance
- Founded
- 2001
- Headquarters
- Louisville, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Mammoth View (KSTC)
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about US WorldMeds on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See US WorldMeds on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.